T cell therapy for advanced pancreatic, colorectal, and lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new treatment using your own immune cells (T cells) that are modified to find and attack cancer cells with a specific genetic change (KRAS G12V or G12D). It is for people with advanced cancer that has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic, colorectal, or lung adenocarcinoma that has progressed after standard treatment or you could not tolerate it.
- You have a specific genetic marker (HLA-A*11:01) and your tumor has a KRAS G12V or G12D mutation.
- You have at least one measurable tumor and are expected to live more than 12 weeks.
- You are in good physical condition (ECOG score 0-1) and have adequate organ function.
- You are willing to use effective contraception for 1 year after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
This trial tests an experimental cell therapy that uses your own immune cells to attack cancers with a specific gene change (KRAS G12V). It may be an option if other treatments haven't worked.
Hear when a new Tumor, Solid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.